Evaluation of Regional Gadolinium Retention in the Brain Using QSM With Correlation to Regional DCE MRI Permeability Using GOCART Technique in Intracranial Neoplasm Patients Receiving Gadobenate Dimeglumine (MultiHance) or Gadoterate Meglumine (Dotarem)
Phase of Trial: Phase II
Latest Information Update: 12 Oct 2018
At a glance
- Drugs Gadobenic acid (Primary) ; Gadoterate-meglumine (Primary)
- Indications Brain cancer
- Focus Diagnostic use
- 03 Oct 2018 Planned End Date changed from 4 Apr 2020 to 4 Apr 2021.
- 03 Oct 2018 Planned primary completion date changed from 4 Apr 2019 to 4 Apr 2020.
- 31 Aug 2018 Biomarkers information updated